Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report
GLP-1 drugs like Ozempic and Zepbound are transforming weight loss and diabetes treatment, with 1 in 8 Americans now taking some form of the medication, according to a study in JAMA
The pharmaceutical segment dominates the market by holding 45.3% of revenue share in 2024 and is expected to expand at more than 6.8% CAGR between 2025 and 2034, with an estimated target valuation exceeding USD 221.5 million by 2034
At the same time, the relationship appears highly complex and influenced by overall diet, gut microbiome composition, metabolic health, and lifestyle
Your Provider will find an appropriate dose for you to finally reach your weight loss goals
Gating schemata were drawn in FlowJo version 10 software (Supplementary Fig